Back to results
US 2026/0226467 A1Published application
Antisense oligomers for treatment of conditions and diseases
AssigneeStoke Therapeutics, Inc.
InventorsIsabel Aznarez, Zhou Han
Life of this patent
Estimating the term…
Abstract
Alternative splicing events in SCN1A gene can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in SCN1A gene can modulate the expression level of functional proteins in Dravet Syndrome patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition caused by SCN1A, SCN8A or SCN5A protein deficiency.
Claims31
(canceled)
A modified antisense oligomer, wherein the modified antisense oligomer comprises at least one modified nucleotide;
- wherein the modified nucleotide comprises a modification of a sugar moiety selected from the group consisting of a 2′-O(CH2)nNH2 modification, a 2′-O(CH2)nCH3, a 2′-O(CH2)nONH2 modification, a 2′-OCH2C(═O)N(H)CH3 modification, a 2′-O(CH2)nON[(CH2)nCH3]2 modification, and any combination thereof, wherein n is an integer from 1 to 10;
- and wherein the modified antisense oligomer comprises a sequence that is complementary to a target sequence of a pre-mRNA in a cell that contains a nonsense-mediated RNA decay inducing exon (NMD exon) and that encodes Nav1.1 protein, whereby hybridization of the modified antisense oligomer to the target sequence modulates splicing of the NMD exon from the pre-mRNA in the cell that contains the NMD exon and that encodes Nav1.1 protein.
Dependencies are inferred from the claim text.